Viridian Therapeutics vs CrowdStrike
Side-by-side comparison of AI visibility scores, market position, and capabilities
Greenwood Village CO YC W20 clinical biotech (NASDAQ: VRDN) with $636.6M cash; veligrotug BLA submission H2 2025 for thyroid eye disease competing with Tepezza; FcRn inhibitor platform with VRDN-003 and VRDN-006 in development.
About
Viridian Therapeutics is a Greenwood Village, Colorado-based clinical-stage biotechnology company — backed by Y Combinator (W20) and publicly traded on NASDAQ (VRDN) — developing FcRn inhibitor therapies for thyroid eye disease (TED) and other serious rare diseases driven by IgG autoantibodies. Maintaining $636.6 million in cash and short-term investments as of March 2025 (sufficient to fund operations into the second half of 2027), Viridian is advancing veligrotug (subcutaneous FcRn inhibitor, BLA submission expected H2 2025 for TED, MAA to EMA expected H1 2026), VRDN-003 (topline clinical data expected H1 2026), and VRDN-006 (proof-of-concept data expected Q3 2025), with $86.6 million in R&D expenses in Q2 2025 reflecting accelerated clinical development investment.
CrowdStrike (CRWD) reported $3.95B ARR in FY2025 (ended Jan). Revenue $3.74B, up 29% YoY. Market cap ~$85B. 8,600+ employees. Austin, TX. AI-native cybersecurity platform. Charlotte AI for threat detection.
About
CrowdStrike is an AI-native cybersecurity company founded in 2011 by George Kurtz, Dmitri Alperovitch, and Gregg Marston and headquartered in Austin, Texas, that built the endpoint detection and response (EDR) category and has since expanded into the broadest cloud-native cybersecurity platform in the industry. The company was founded on the insight that traditional antivirus software — signature-based, retrospective, and endpoint-isolated — could not keep pace with sophisticated adversaries operating at machine speed. CrowdStrike's founding architecture, the Falcon platform, was designed cloud-native from day one: a single lightweight agent on the endpoint feeding a cloud-based AI that learns from trillions of security events across every customer simultaneously. The company trades on Nasdaq under the ticker CRWD.\n\nThe CrowdStrike Falcon platform consolidates more than 28 security modules across endpoint security, identity threat protection, cloud security, next-gen SIEM and log management, threat intelligence, and managed detection and response — all delivered through a single agent and unified console. The AI at the platform's core, Charlotte AI, provides conversational security operations, automated investigation, and AI-generated threat summaries that reduce analyst workload. CrowdStrike's threat intelligence team, Adversary Intelligence, tracks and names nation-state and criminal threat actors globally, giving customers predictive insight into campaigns before they hit their environments.\n\nCrowdStrike reported $3.95 billion in annual recurring revenue (ARR) for FY2025 and total revenue of $3.74 billion, up 29% year over year, with a market capitalization of approximately $85 billion. The company has 8,600+ employees and counts a substantial share of the Fortune 500 and global governments as customers. Despite the July 2024 sensor update incident that caused a significant IT outage affecting millions of Windows systems globally, CrowdStrike's customer retention remained strong — a testament to the platform's depth of integration and the switching costs built into its consolidated architecture.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.